摘要
目的:探讨α肾上腺素能受体(α-AR)阻滞剂特拉唑嗪联合氯美扎酮治疗慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)的疗效和安全性。方法:将168例CP/CPPS患者随机分成3组:特拉唑嗪组58例、氯美扎酮组38例和特拉唑嗪+氯美扎酮组72例,每组患者均接受药物治疗4周。采用美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评分作为疗效指标,分别评价各组患者的疗效和药物不良反应。结果:159例完成了4周的治疗并接受最终评估,其中特拉唑嗪组55例、氯美扎酮组35例、特拉唑嗪+氯美扎酮组69例。3组患者的NIH-CPSI总分治疗前后平均分别下降7.90、5.92、8.92分,与治疗前相比均有显著性差异(P<0.05)。特拉唑嗪+氯美扎酮组较特拉唑嗪组和氯美扎酮组总分下降均有显著性差异(P<0.05)。药物不良反应包括体位性低血压(特拉唑嗪组17.1%,特拉唑嗪+氯美扎酮组15.4%)、射精障碍(仅特拉唑嗪组3.4%)和倦怠、疲乏和厌食等(氯美扎酮组18.5%,特拉唑嗪+氯美扎酮组12.6%)。因不良事件终止治疗的共9例,其中特拉唑嗪组3例(5.2%)、氯美扎酮组3例(7.9%)、特拉唑嗪+氯美扎酮组3例(4.2%)。结论:特拉唑嗪、氯美扎酮均能有效缓解CP/CPPS患者的症状,改善患者的生活质量,两者联合治疗疗效优于单一治疗。
Objective ： To investigate the efficacy and safety of the α1-receptor inhibitor terazosin combined with chlormezanone in the treatment of chronic prostatitis / chronic pelvic pain syndrome （CP/CPPS）. Methods ： A total of 168 CPPS patients, aged 20 - 50 （mean 32.9） years and with the disease course of 3 months to 7 years （mean 17 months） , were equally randomized into a terazosin group （n = 58）, a chlormezanone group （n = 38） and a terazosin ＋ chlormezanone （T ＋ C） group （n = 72） , and treated accordingly for 4 weeks. All the patients were scored on NIH-CPSI （ National Institute of Health-Chronic Prostatitis Symptom Index） after the treatment and the therapeutic effects were compared among the three groups. Results ： Of the total number of patients, 159 completed the treatment and were evaluated, including 55 of the terazosin group, 35 of the chlormezanone group and 69 of the T ＋ C group. After the treatment, the NIH-CPSI scores of the three groups decreased from 24.05 ± 3.02 to 16.15 ± 3.25 （ mean 7.90） , from 23.43 ± 3.58 to 17.51 ± 3.08 （mean 5.92）, and from 23.93 ± 3.30 to 15.01 ± 3.08 （mean 8.92）, respectively, with statistically significant differences from pretreatment （P 〈 0.05） as well as between the combined therapy group and the other two （P 〈 0.05 ）. The adverse events included postural hypotension （ 17. 1% in the terazosin group and 15.4% in the T ＋ C group）, dysspermatism （3.4% in the terazosin group only） , lassitude, fatigue and anorexia （ 18.5% in the chlormezanone group and 12.6% in the T ＋ C group）, Nine of the patients failed to accomplish the treatment because of adverse events, 3 （5.2%） in the terazosin group, 3 （ 7.9% ） in the chlormezanone group and 3 （ 12.6% ） in the T ＋ C group. Conclusion ： Both terazosin and chlormezanone can re lieve the symptoms in CF/CPPS patients and improve their life quality, but their combined use may produce a better efficacy than either terazosin or chlorm
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2009年第8期717-720,共4页
National Journal of Andrology
